“OC18 | LONG-TERM EFFECTIVENESS, SAFETY AND TOLERABILITY OF ATOGEPANT IN THE PREVENTION OF MIGRAINE: A MULTICENTRIC, PROSPECTIVE OBSERVATIONAL, REAL WORLD STUDY (THE 48-WEEK STAR STUDY): F. Vernieri1|2, L. Francesco Iannone3, M. Marcosano1|2, L. Fofi1, F. Lo Castro4, G. Sebastianelli5, F. De Santis6, M. Corrado7, R. Ornello6, L. Grazzi8, D. Antonio Montisano8, F. De Cesaris9, A. Munafò9, G. Avino10, M. Trimboli11, M. Albanese12, A. Russo13, M. Silvestro13, G. Dalla Volta14, M. Romozzi15, P. Calabresi15, A. Boccalini4, P. Merlo16, M. Pia Prudenzano17, M. Rosaria Valente18, I. Rainero19, G. Giuliani20, M. Altieri20, A. Doretti21, G. Vaghi7|22, F. Pistoia6, D. Ferrandi23, S. Battistini24, G. Coppola5, S. Guerzoni4, S. Sacco6|25, C. Tassorelli7|22, C. Altamura1|2 | 1Headache and Neurosonology Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; 2Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Italy; 3Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Italy; 4Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico Di Modena, Italy; 5Sapienza University of Rome, Department of Medico-Surgical Sciences and Biotechnologies, Polo Pontino, Latina, Italy; 6Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Italy; 7Headache Science and Neurorehabilitation Centre, IRCCS Mondino Foundation, Pavia, Italy; 8Headache Center IRCCS Fondazione Istituto Neurologico "Carlo Besta", Italy; 9Headache center and clinical pharmacology, AOU Careggi, Firenze, Italy; 10Neurology Unit, Ospedale Santo Stefano, USL Toscana Centro, Prato, Italy; 11Azienda Ospedaliera-universitaria "Renato Dulbecco", Catanzaro, Italy; 12Department of Systems Medicine, University of Rome Tor Vergata, Italy; 13Headache Center, Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, Second University of Naples, Italy; 14U.O Neurologia, Istituto Clinico Città di Brescia, Gruppo San Donato, Italy; 15Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; 16UO di Neurologia, Humanitas Gavazzeni, Bergamo, Italy; 17Clinica Neurologica ‘L. Amaducci’, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Italy; 18Clinica Neurologica ASUFC, Dipartimento di Medicina DMED Università di Udine, Italy; 19Headache Center, Department of Neuroscience, University of Torino, Italy; 20Department of Human Neuroscience, Sapienza University of Rome, Italy; 21IRCCS Istituto Auxologico Italiano, Milano, Italy; 22Department of Brain and Behavioural Sciences, University of Pavia, Italy; 23SC Neurologia, Azienda Ospedaliero Universitaria Santi Antonio e Biagio, Alessandria, Italy; 24Department of Medical, Surgical and Neurological Sciences, University of Siena, Italy; 25Neurology and Stroke Unit, ASL 1 Abruzzo, Avezzano-Sulmona-L’Aquila, Italy” (2026) Confinia Cephalalgica, 36(s1). doi:10.4081/cc.2026.15956.